Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT01371981]

Bio2RDF uri

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT01371981]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT01371981

Bio2RDF identifier

NCT01371981

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01371981

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01371981

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

1,250

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01371981 arm group 05db47a1f95d4565accbbc04d387dada [clinicaltrials_resource:NCT01371981/arm-group/05db47a1f95d4565accbbc04d387dada]

NCT01371981 arm group 0acf1bf4bb65abca4ef7b74243358c07 [clinicaltrials_resource:NCT01371981/arm-group/0acf1bf4bb65abca4ef7b74243358c07]

NCT01371981 arm group 1bdaa98ab0c4148bdf9102aa867d0123 [clinicaltrials_resource:NCT01371981/arm-group/1bdaa98ab0c4148bdf9102aa867d0123]

NCT01371981 arm group 22ab3ec02abf0a7ab8f5962ef47539b1 [clinicaltrials_resource:NCT01371981/arm-group/22ab3ec02abf0a7ab8f5962ef47539b1]

NCT01371981 arm group 2b720522815c694f9f770cc80f1b27cd [clinicaltrials_resource:NCT01371981/arm-group/2b720522815c694f9f770cc80f1b27cd]

NCT01371981 arm group 394251f480f141c731377faac3af77a6 [clinicaltrials_resource:NCT01371981/arm-group/394251f480f141c731377faac3af77a6]

NCT01371981 arm group 3f661fa8ed4e8e0ded08f214591f8c2e [clinicaltrials_resource:NCT01371981/arm-group/3f661fa8ed4e8e0ded08f214591f8c2e]

NCT01371981 arm group 570a8d769543cd5559e2519f969e40f0 [clinicaltrials_resource:NCT01371981/arm-group/570a8d769543cd5559e2519f969e40f0]

NCT01371981 arm group 61c82f9c536128ba5fffcc1286c58ec3 [clinicaltrials_resource:NCT01371981/arm-group/61c82f9c536128ba5fffcc1286c58ec3]

NCT01371981 arm group 6c3bc8eba6241e98b86499c9c8f04671 [clinicaltrials_resource:NCT01371981/arm-group/6c3bc8eba6241e98b86499c9c8f04671]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

This randomized phase I ...... acute myeloid leukemia.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Bortezomib and Sorafenib Tosyl ...... agnosed Acute Myeloid Leukemia

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:d7070d44c51429851f9b047752ac6e61]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:215c1935df5e0cbbdf94f93372bfb64c]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:3efc3fd3d331a787b1eb58693523209c]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:4c590b343064bbc7a624f7671a98acc1]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:4fdeab107ac8c243b3be7c31534bd464]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:5535cba147301dcf26a173cbc1528917]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:7f2cb7f4c0917553e6b1648e4786ecd1]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:85505f441c4c25b346f3898069655f7b]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:86b62ba465fc6ca3b259685c18f5bdf7]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:8ade9b748327de6245ffb71468d6dea2]

EFS From the time on study to induction failure, relapse or death, up to 11 years [clinicaltrials_resource:93d6f759cd2398516edf24c46a8423a7]

detailed description [clinicaltrials_vocabulary:detailed-description]

PRIMARY OBJECTIVES: ...... then yearly thereafter.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01371981 [clinicaltrials_resource:cfe30df1f870f26599157c9787636852]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2011-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Questionnaire Administration [clinicaltrials_resource:25274337cac6d980fb228c2dfc9bacc1]

Etoposide [clinicaltrials_resource:31c5170549810ad9080608ee57b3e176]

Sorafenib Tosylate [clinicaltrials_resource:507c94f61cb664da0d566661fba004ee]

Quality-of-Life Assessment [clinicaltrials_resource:6d0038d7fb54cd592a0b0b68e26128f7]

Cytarabine [clinicaltrials_resource:79c90e549b607db78e79fe6f89d0f6f7]

Pharmacological Study [clinicaltrials_resource:830075e0450be27d533f57148f33c574]

Daunorubicin Hydrochloride [clinicaltrials_resource:9adc99c9e9f6d8c7a833d627c387200d]

Asparaginase [clinicaltrials_resource:a954bb6b52e1a47acc6dda4f83e793be]

Bortezomib [clinicaltrials_resource:c858f982ab3fe81d8cf6c70849ffb471]

Laboratory Biomarker Analysis [clinicaltrials_resource:d9b22f21aa950ebe7682b366ecc738bb]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Asparaginase [clinicaltrials_resource:1f5684df551970c7aa9ac989326fceb3]

Cytarabine [clinicaltrials_resource:22c1374b2123aed8146827c85013eca8]

Sorafenib [clinicaltrials_resource:31f520fac457a753e5cebbd3f35354d4]

Niacinamide [clinicaltrials_resource:87fd34b41aab380ff4fcb174e0cb1909]

Etoposide [clinicaltrials_resource:9da7c67aeb381d243aa9355f549b8443]

Mitoxantrone [clinicaltrials_resource:aab984cd02fb960e283b5217edf826bc]

Etoposide phosphate [clinicaltrials_resource:c16b1010e56ec897fd8124c88360bb44]

Bortezomib [clinicaltrials_resource:e28b6867d67df196e61715b986db5f30]

Daunorubicin [clinicaltrials_resource:e5ea0c80dc8d41e5d3a34f69e1976c7e]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

National Cancer Institute (NCI) [clinicaltrials_resource:a5725923b7e37779ae6f8b04acb7f59c]

location [clinicaltrials_vocabulary:location]

Children's Hospital of Alabama [clinicaltrials_resource:61e699d8adf83cc69a48990815244ae7]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01371981

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase III Randomized Trial f ...... th High Allelic Ratio FLT3/ITD

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

NCI-2011-02670

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Richard Aplenc [clinicaltrials_resource:62bdabfcaa1e20c7043e70ffff8d7aea]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

NCI-2011-02670

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

National Cancer Institute (NCI) [clinicaltrials_resource:a5725923b7e37779ae6f8b04acb7f59c]

start date [clinicaltrials_vocabulary:start-date]

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01371981 study design [clinicaltrials_resource:cda2345dc02b6f3b10efd8780e343543]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01371981

verification date [clinicaltrials_vocabulary:verification-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01371981

http://www.w3.org/2001/XMLSchema#string

title

Bortezomib and Sorafenib Tosyl ...... agnosed Acute Myeloid Leukemia

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Bortezomib and Sorafenib Tosyl ...... a [clinicaltrials:NCT01371981]

@en